See What HealthDay Can Do For You
Contact Us

December 2007 Briefing - HIV & AIDS

Here are what the editors at HealthDay consider to be the most important developments in HIV & AIDS for December 2007. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.

Effect of Helminth Treatment on HIV Unclear

WEDNESDAY, Dec. 26 (HealthDay News) -- Existing data is insufficient to establish the potential benefit of eradicating helminth infections in adults also infected with HIV-1; however, data from a handful of studies indicate that it may reduce plasma viral load. These findings were published Dec. 19 in PLoS Neglected Tropical Diseases.

Full Text

Semen Protein Enhances HIV Infection

MONDAY, Dec. 17 (HealthDay News) -- An abundant protein found in human semen dramatically enhances HIV infection by forming fibrils that promote the capture and attachment of HIV virions to target cells, according to study findings published in the Dec. 14 issue of Cell.

Abstract
Full Text

Sharp Decline of Comorbidity of Tuberculosis and HIV

FRIDAY, Dec. 14 (HealthDay News) -- Comorbid cases of tuberculosis (TB) and HIV declined sharply in the United States between 1993 to 2004, researchers report in the Dec. 10/24 issue of the Archives of Internal Medicine.

Abstract
Full Text (subscription or payment may be required)

Conflicting Data on Steroid Use in Bacterial Meningitis

WEDNESDAY, Dec. 12 (HealthDay News) -- A study of adults in sub-Saharan Africa with acute bacterial meningitis showed no benefit of corticosteroid adjuvant therapy, while a study of Vietnamese adults and adolescents reported a beneficial effect in only those with microbiologically confirmed disease, according to research published in the Dec. 13 issue of the New England Journal of Medicine.

Abstract - Scarborough
Full Text (subscription or payment may be required)
Abstract - Mai
Full Text (subscription or payment may be required)
Editorial

Tesamorelin Associated with Reduction in Visceral Fat

WEDNESDAY, Dec. 5 (HealthDay News) -- The growth hormone-releasing factor tesamorelin may be helpful in reducing visceral fat and improving lipid profiles in patients with HIV who are receiving antiretroviral therapy, according to research published in the Dec. 6 issue of the New England Journal of Medicine.

Abstract
Full Text (subscription or payment may be required)
Editorial

Cytomegalovirus Retinitis Is Neglected HIV Complication

MONDAY, Dec. 3 (HealthDay News) -- In developing nations, cytomegalovirus (CMV) retinitis is a commonly overlooked but highly treatable complication of HIV infection, according to a report published in the December issue of PLoS Medicine.

Full Text

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.